Viatris downgraded by BMO Capital Markets with a new price target

2/17/23 7:54:18 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BMO Capital Markets downgraded Viatris from Outperform to Market Perform and set a new price target of $14.00 from $16.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VTRS

Date	Price Target	Rating	Analyst
6/6/2025	$10.00	Neutral	Goldman
7/19/2024	$15.00	Buy	Jefferies
10/23/2023	$13.00 → $9.00	Neutral → Underperform	BofA Securities
6/23/2023	$11.00	Equal Weight → Underweight	Barclays
4/24/2023	$11.00	Overweight → Equal Weight	Barclays
2/17/2023	$16.00 → $14.00	Outperform → Market Perform	BMO Capital Markets
1/27/2023	$13.00 → $15.00	Hold → Buy	Jefferies
11/10/2022	$9.00 → $12.00	Sell → Neutral	UBS